Thus, the therapeutics access is mainly focused on the inhibition of AChE and N-methyl-D-aspartate (NMDA) receptors for treating Alzheimer's disease currently [24, 25]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.